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ABSTRACT The nicotinic acetylcholine receptor is the
prototype ligand-gated ion channel. A number of aromatic
amino acids have been identified as contributing to the agonist
binding site, suggesting that cation–p interactions may be
involved in binding the quaternary ammonium group of the
agonist, acetylcholine. Here we show a compelling correlation
between: (i) ab initio quantum mechanical predictions of
cation–p binding abilities and (ii) EC50 values for acetylcho-
line at the receptor for a series of tryptophan derivatives that
were incorporated into the receptor by using the in vivo
nonsense-suppression method for unnatural amino acid in-
corporation. Such a correlation is seen at one, and only one,
of the aromatic residues—tryptophan-149 of the a subunit.
This finding indicates that, on binding, the cationic, quater-
nary ammonium group of acetylcholine makes van der Waals
contact with the indole side chain of a tryptophan-149,
providing the most precise structural information to date on
this receptor. Consistent with this model, a tethered quater-
nary ammonium group emanating from position a149 pro-
duces a constitutively active receptor.
The nicotinic acetylcholine receptor (nAChR) is the longest
known, best studied neuroreceptor (1, 2). It defines a super-
family that also includes receptors for serotonin, g-aminobu-
tyric acid, and glycine, as well as an invertebrate glutamate-
gated channel. The nAChR functions at the vertebrate neu-
romuscular junction and in the central nervous system, and
nicotine binding to the nAChR represents the initial chemical
step in nicotine addiction. The receptor comprises five ho-
mologous subunits, arranged in a pentagonal array around a
central pore that is presumed to be the ion channel (3). The
embryonic muscle form of the receptor has a subunit stoichi-
ometry of a2bgd, and much work has established an important
role for the a subunits in defining the agonist binding site.
Pioneering photoaffinity labeling studies by Changeux identi-
fied a number of residues that are near the agonist binding site,
and, surprisingly, all such residues are aromatic—Tyr or Trp
(1). Subsequent studies confirmed important functional roles
for many of these aromatics (4–6). An elegant crosslinking
study by Karlin implicated an anionic residue on the gyd
subunits that also influences agonist binding (7). These find-
ings are summarized in Fig. 1.
The large number of aromatic amino acids at the agonist
binding site of the nAChR led to the proposal that cation–p
interactions may be important in binding acetylcholine (ACh)
(8). The cation–p interaction is a general noncovalent binding
force, in which the face of an aromatic ring provides a region
of negative electrostatic potential that can bind cations with
considerable strength (9, 10). In a biological context, it is the
aromatic side chains of Phe, Tyr, and Trp that can be expected
to be involved in cation–p interactions, and a large body of
evidence indicates a prominent role for cation–p interactions
in structural biology in general (9, 11). The physical under-
pinnings of the cation–p interaction are now well understood,
so that one can use ab initio quantum mechanical calculations
on small model systems to predict with some confidence how
modifications of an aromatic system should affect its cation–p
binding ability (12, 13). This knowledge, combined with ex-
tensions to site-directed mutagenesis allowing for in vivo
unnatural amino acid incorporation (14–19) allows the sys-
tematic evaluation of potential cation–p binding sites. Previ-
ously, we have used unnatural amino acid mutagenesis to
evaluate three conserved tyrosines at the agonist binding site
(Fig. 1) (14, 20), with no results that suggested a cation–p
interaction. However, theoretical studies of the cation–p in-
teraction (12) and surveys of protein structures (10) clearly
indicate that, of the natural amino acids, Trp presents the most
potent cation–p binding site. We now report studies of four
different tryptophans implicated in ACh binding (Fig. 1). At
one, and only one, site—aTrp-149—EC50 correlates strongly
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FIG. 1. Structural features of the nAChR. (Left) Global layout,
adapted from data by Unwin (3), but with alternative ordering of
subunits around the central axis (2, 20). (Right) Schematic of the
agonist binding site (gray oval) viewed from the synapse, showing the
large number of aromatic residues from three noncontiguous regions
of the a subunit and key residues from the d subunit also thought to
contribute to binding. A comparable arrangement exists at the ayg
interface. Adapted from drawings previously presented by Galzi and
Changeux (1) and Karlin and Akabas (2). Amino acid codes: W,
tryptophan, Y, tyrosine, D, aspartate.
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with the cation–p binding ability of the aromatic side chain.
We take this correlation as clear evidence that the a149 side
chain is in van der Waals contact with the quaternary ammo-
nium group of ACh in the bound state of the receptor.
Consistent with this model, a tethered quaternary ammonium
group emanating from position a149 produces a constitutively
active receptor.
METHODS
General Procedures. Protocols for mutagenesis, mRNA
preparation, aminoacyl-tRNA synthesis, oocyte injection, and
electrophysiology are as described in several previous publi-
cations (14, 15, 20). The patch pipette and bath solutions for
single channel recording were 115 mM NaCly10 mM Hepes—
NaOHy1 mM CaCl2y2 mM KCl, pH 7.4. Patch recordings were
conducted at room temperature 36 h after mRNA injection.
Single-channel currents were filtered at 5 kHz and stored on
a digital data recorder (48-kHz sampling rate, Neuro-corder
DR-384, Neuro Data Instruments, New York). The data were
played back, redigitized at 20 kHz, and filtered at 3 kHz.
Synthesis of Unnatural Amino Acids. Unnatural amino acids
were either commercially available or were prepared by using
a method developed by Roberts et al. (21). This method
simplifies the synthesis of Trp analogs to the synthesis of the
corresponding indole side chains. In most cases, indole syn-
thesis followed standard procedures. Tetrafluoroindole was
prepared by the method of Rajh (22). 5,7-Difluoroindole and
5,6,7-trif luoroindole were prepared by the reaction of CuIy
dimethylformamide with the analogous 6-trimethylsilylacety-
lenylaniline [the latter prepared by reaction of the fluorinated
aniline with trimethylsilylacetylene catalyzed by bis(triphen-
ylphosphine)palladium dichloride and CuI (23)]. Nvoc-Tyr-
O3Q (Nvoc, 6-nitroveratryloxycarbonyl) cyanomethyl ester
was prepared by reaction of Nvoc-4-O-(3-iodopropyl)tyrosine
cyanomethyl ester with trimethylamine. Further synthetic de-
tails are available in ref. 24. Structures of all the pdCpA-amino
acid conjugates were confirmed by fast atom bombardment or
electrospray ionization–MS analysis.
RESULTS AND DISCUSSION
Using nonsense codon suppression procedures and oocyte
expression, we incorporated and evaluated electrophysiologi-
cally (14, 15) a series of Trp derivatives at four sites of the
mouse muscle nAChR—a86, a149, a184, and g55yd57—all of
which are naturally Trp and all of which have been implicated
in defining the agonist binding site (Fig. 1). Fig. 2 shows Trp
derivatives that have been incorporated by the suppression
method at one or more of these sites. At all sites and for all
derivatives, responses display hallmarks of functional nAChR
molecules: desensitization with prolonged exposure to agonist,
and dose-response relations with Hill coefficients between 1
and 2 (Fig. 3).
Strongly electron-withdrawing groups such as cyano (CN)
and fluoro substantially weaken the cation–p interaction.
Fluorine is generally considered to be a substituent that
provides a negligible steric perturbation, and so direct com-
parison of fluorinated tryptophans with the wild type is
justified. In considering the CN group, modeling shows that
5-Br-Trp and 5-CN-Trp are quite similar in size, but they differ
considerably in cation–p binding ability, making this also a
useful comparison. Such a comparison is greatly preferable to,
for example, 5-CN-Trp vs. Trp, where both steric and elec-
tronic structure are changing.
At three sites—a86, a184, and g55yd57—4,5,6,7-F4-Trp,
5-CN-Trp, and 5-Br-Trp gave EC50 values for ACh that were
not largely different (,2-fold) from wild type (Table 1), ruling
out a strong cation–p interaction at these sites. The results for
4,5,6,7-F4-Trp support the notion that F does not provide a
strong steric perturbation.
At aTrp-149, however, a very different pattern is seen
(Table 2). 5-CN-Trp gives an EC50 that is very much greater
than wild type and, importantly, much greater than 5-Br-Trp.
To further establish that this is not a steric effect, we deter-
mined that 5-Me-Trp, which is sterically similar to 5-CN- and
5-Br-Trp but resembles wild-type Trp in a cation–p interac-
tion, shows wild-type behavior (Table 2). Strongly electron-
withdrawing groups such as CN or F could influence the
hydrogen-bonding ability of the indole NH. However, any
prominent role for such a hydrogen bond is ruled out by several
mutants of Table 2 [N-Me-Trp, 1-Np-Ala, 2-Np-Ala, and
benzothienylalanine (Np, naphthylalanine)]. Note that the
EC50 for 5-CN-Trp is too large to be accurately measured
directly, because at the ACh concentrations required to cover
the dose–response relation, ACh itself becomes an effective
FIG. 2. Structures of Trp derivatives incorporated by the nonsense-suppression method. Bta, benzothienylalanine; Np-Ala, naphthylalanine.
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channel blocker. As in previous work (20), we have rendered
these relatively insensitive receptors more responsive by in-
troducing a single Leu-993 Ser mutation in the M2 region of
the b subunit (residue 262) (25, 26). This mutation lowers EC50
by a consistent factor of '40, but by itself does not activate
receptors. The M2 99 residue is thought to lie some 50 Å from
the binding site, and for the muscle receptor, the increased
sensitivity probably arises because the channel is open longer
and opens more frequently (C. Labarca, G. N. Filatov, H.
Zhang, J. Li, and H.A.L., unpublished work), rather than
because a desensitized state becomes conducting, as occurs for
the analogous mutation in the homomultimeric a7 receptor
(27). It remains formally possible that there are subtle changes
in the structure of the binding site because of incorporation of
the 99 mutation (H. Zhang, P. Deshpande, C. Labarca, H.A.L.,
and J. Li, unpublished work) (28). The validity of extending the
measurable range of ACh sensitivities by using the bLeu-993
Ser mutation is supported by three entries in Table 2 (Trp,
5-Br-Trp, and 5-F-Trp), for which the ratios of EC50 values
with and without the 99 mutation are the same.
While the results with 5-CN-Trp were suggestive, the most
intriguing data come from studies of the fluorinated Trp
derivatives. Beginning with 5-F-Trp and moving on to di-, tri-,
and tetrafluoro derivatives produces a series of closely related
compounds with substantial electronic but minimal steric
changes. Within such a series, the ever-present concerns that
FIG. 3. (A) Representative voltage-clamp current traces from oocytes expressing Trp (wild type, Left) and 5,7-F2-Trp (Right) at a149. Bars
represent application of ACh (mM). (B) Dose–response relations and fits to the Hill equation for (left to right): Trp; 5-F-Trp; 5,7-F2-Trp;
5,6,7-F3-Trp; and 4,5,6,7-F4-Trp. EC50 values are given in Table 2. (C) Plot of log[EC50yEC50(wild type)] vs. quantitative cation–p binding ability
at a149 for the same residues as in B. Data are from Table 2. The data fit the line y 5 3.2 2 0.096x, with a correlation coefficient r 5 0.99. Error
bars are approximately the size of the markers.
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site-directed mutagenesis has led to major structural reorga-
nizations are minimized. This level of control over structural
perturbations represents a substantial advantage of the unnat-
ural amino acid method.
As shown in Table 2, progressive fluorination at position
a149 leads to a systematic increase in EC50. We have devel-
oped previously a quantitative measure of cation–p binding
ability for simple ring systems. Briefly, the method (12, 13)
involves ab initio quantum mechanical calculation of the
binding energy for a Na1 ion to the ring of interest. Fig. 3C
shows that fluorination at position a149 produces a compelling
correlation between EC50 and cation–p binding ability. Over
a range of nearly two orders of magnitude in EC50, a linear
relationship is seen between log(EC50) and the quantitative
cation–p binding ability of the side chain.
Of course, EC50 is not a binding constant—it is a composite
number reflecting both agonist binding and gating. By making
the plot of Fig. 3C, we are not assuming that gating is
unimportant; we are only assuming that variations in EC50
across this series of closely related structures occur primarily
because of variations in agonist binding. This is a reasonable
assumption, given the location of the residue. Similarly, the
cation–p calculations ignore solvation issues and entropy
effects and model ACh as a much simpler ion. The plot of Fig.
3C does not assume these effects are negligible, only that they
are relatively constant across the series. On going from one
point to the next in Fig. 3C, all that is changing is one H to F
in a molecular weight 290,000 protein—it is hard to imagine,
for example, that dramatic changes in DS would result from
such a change. The high quality of the correlation suggests that
we have isolated an important interaction in the receptor—a
cation–p interaction at aTrp-149.
To the extent that EC50 can be considered as proportional
to a binding constant in this particular situation, log(EC50) is
the appropriate quantity to compare with the cation–p binding
energy. The EC50 change on going from Trp to 4,5,6,7-F4-Trp
corresponds to $2 kcalymol of binding energy. This is a
substantial quantity for disruption (but not deletion) of a single
noncovalent contact, and it requires that the ACh and the Trp
side chain are interacting directly.
Table 2 presents EC50 values for all the derivatives of Fig. 2,
and inclusion of these data produces a similar plot (correlation
coefficient r 5 0.90). Although the range spanned by the
additional entries is not large, for most of the residues a
decrease in cation–p binding implies an increase in EC50.
There are a few outliers, as expected for a much broader range
of structural variation. The EC50 value for 5-NH2-Trp is much
higher than expected, and the differences among the various
monofluoro tryptophans are not easily rationalized. These
differences could indicate specific interactions in the receptor,
and the 5-NH2-Trp result in particular is under further inves-
tigation in relation to the possibility that the amine is proton-
ated in the receptor.
We consider the data of Table 2 and Fig. 3C to provide
convincing evidence that the quaternary ammonium group of
ACh makes close contact with the side chain of aTrp-149 in the
nAChR. Note that the maximum in cation–p binding occurs
over the six-membered ring of Trp (9, 13), and the calculated
cation–p binding energies of Table 2 and Fig. 3C involve such
a geometry, so the quaternary ammonium of ACh must be
positioned over the 6-ring of aTrp-149 (Fig. 4). Since the
aromatic rings of Phe and Tyr align with the 5-ring of Trp —
poorly positioned for a binding interaction — one might expect
them to perform poorly at a149. Indeed, Changeux has found
that an analogous Trp-to-Phe mutation in the a7 neuronal
nAChR markedly increased EC50 (29), and we find that the
same mutation at a149 in the muscle-type receptor increases
EC50 roughly 100-fold.
Table 2. EC50 and cation-p binding ability for various Trp
mutants at position a149
Side chain*
Cation–p
binding,†
kcalymol
EC50,‡§
mM
Corrected
EC50,§¶
mM
Trp 32.6 1.2 50
5-F-Trp 27.5 4.7 200
5,7-F2-Trp 23.3 13 (550)\
5,6,7-F3-Trp 18.9 34 (1400)\
4,5,6,7-F4-Trp 14.4 65 (2700)\
5-Br-Trp 27.8 2.0 88
5-CN-Trp 21.5 114 (4750)\
5-Me-Trp 33.4 — 49
4-F-Trp 27.9 — 56
6-F-Trp 27.4 — 48
1-Np-Ala 28.9 — 51
2-Np-Ala 28.9 — 82
7-aza-Trp 26.0 — 130
Bta 26.9 — 174
N-Me-Trp 33.7 — 95
5-NH2-Trp 36.4 280
*See Fig. 2 for side-chain structures.
†The cation-p binding is defined as the negative of the binding energy
(kcalymol) of a generic probe cation (Na1) to the appropriate
aromatic ring using ab initio HF 6-31G** calculations with full
geometry optimization, as described previously (12). Since the
6-31G** basis set is not available for Br, the 6-311G** basis set was
used for 5-Br-Trp, and then the value was corrected based on a linear
correlation (r 5 0.997) between binding energies for a collection of
ten aromatics determined with the two different basis sets. Calcula-
tions were performed with GAUSSIAN 94 (34) or SPARTAN (35).
‡For receptors with a bLeu-99 3 Ser mutation, see text.
§Hill coefficients are generally in the range 1.3–1.8, but for the
relatively insensitive structures (5-CN-Trp and 4,5,6,7-F4-Trp with
bLeu-99 3 Ser mutations), values as low as 1.0 are observed.
¶For receptors that are otherwise wild type.
\Obtained by multiplying the entries of the adjacent column by a
constant factor of 42, to compensate for the bLeu-993 Ser mutation;
see text.
Table 1. EC50 for selected Trp mutants at a86, a184, and g55yd57,
showing that all three sites are substantially insensitive to the
electronic properties of the Trp side chain
Side chain*
EC50,† mM
a86 a184 g55yd57‡
Trp 50 50 50
5-Br-Trp 53 48 23
5-CN-Trp 61 46 25
4,5,6,7-F4-Trp 45 62 92
*See Fig. 2 for side-chain structures.
†Hill coefficients are all in the range 1.5–2.0.
‡For all studies of this Trp, mutations were introduced into both the
g55 and d57 sites, and both mutant subunits were expressed, so both
agonist binding sites have the mutant Trp.
FIG. 4. (Left) Schematic of the quaternary ammonium of ACh
positioned over the 6-ring of aTrp-149. (Right) Structure of Tyr-O3Q,
showing that the tethered quaternary ammonium can be positioned in
roughly the same location as the quaternary ammonium of ACh.
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The model proposed here provides the most precise
information to date on the location of ACh when bound to
the nAChR. This model suggests that any means of posi-
tioning a quaternary ammonium in close proximity to aTrp-
149 might produce an active receptor. In classic experiments,
tethered agonists were obtained by attaching structures
containing quaternary ammonium groups to the cysteines
produced by reducing the highly conserved Cys-192-Cys-193
disulfide of the a subunit, leading to the conclusion that the
quaternary ammonium group interacts with a moiety within
9 Å of the disulfide (30, 31). We applied a similar strategy
at position a149, incorporating the unnatural amino acid
Tyr-O3Q (Tyr-O-(CH2)3-N(CH3)3
1, see Fig. 4). Modeling
clearly shows that the quaternary ammonium of Tyr-O3Q
can achieve the same position as that proposed in the binding
of ACh.
As shown in Fig. 5, incorporation of Tyr-O3Q at position
a149 produces a constitutively active receptor. In the absence
of added ACh, standing inward currents (500–3000 nA, Fig.
5A) and substantially reduced resting membrane potentials are
consistently seen in Xenopus oocytes expressing the mutant
channel. The standing currents are presumably partially de-
sensitized due to the prolonged activation. The standing
currents are inhibited by a-bungarotoxin, a specific, high-
affinity antagonist for nicotinic receptors (data not shown).
Exposure of the oocytes to channel blockers such as QX-314
and TMB-8 or the competitive antagonist d-tubocurarine
(dTC) immediately and reversibly reduces the standing inward
current (Fig. 5A) and leads to more typical resting membrane
potentials. We note that the tethered quaternary ammonium
appears to be a fairly weak agonist, as standing currents are
observed only when the previously mentioned Leu-99 3 Ser
mutation is incorporated into the M2 region of the b subunit.
Application of ACh produces additional inward currents (Fig.
5 A and B), in agreement with the idea that the tethered
quaternary ammonium group is a partial agonist; apparently,
additional features of the ACh molecule are required for full
activation. Blockage by dTC appears to be roughly half-
maximal at a value (50 nM, Fig. 5A) near its Ki for wild-type
receptor (14). This result suggest that the dTC binding site does
not overlap with the cation–p site or that the tethered group
can be displaced by dTC. Prolonged exposure (.3 min) to high
ACh concentrations led to desensitization of both the standing
currents (Fig. 5B) and the responses to further ACh applica-
tions (data not shown), further evidence that the response
arises directly from nAChR. Single-channel recordings showed
that the standing current was due to openings of 43-pS
conductance (Fig. 5C), quite comparable to the wild-type
nAChR (42 pS). The combined data of Fig. 5 clearly establish
that positioning a quaternary ammonium group very near the
region normally occupied by aTrp-149 can be enough to
activate the receptor.
FIG. 5. (A) Standing inward currents and ACh responses in oocytes
expressing nAChRs with Tyr-O3Q incorporated at a149 and a Leu-99
3 Ser mutation in M2 of the b subunit. The initial current of almost
23 mA, the standing current as a result of the mutant channels, is
substantially eliminated by channel blockers such as QX-314 and
TMB-8 or the cholinergic antagonist dTC. Application of ACh leads
to increased currents. (B) ACh-induced desensitization affects the
standing current. During the first application of TMB-8 (5 mM), the
standing outward current was reduced reversibly to nearly zero. ACh
(25 mM) was then added, inducing an inward current that desensitized.
During the desensitization phase, the standing current was reduced.
TMB-8 was added again during the desensitization phase. The TMB-8
deflection reached the former plateau level rather than producing a
net outward current. These interactions show that ACh desensitizes
the conductance mechanism that produces the standing current;
therefore, the standing current is produced by functional nAChR. (C)
Single-channel records and open-time distribution from receptors
containing Tyr-O3Q at position a149. The traces show selected
openings from cell-attached patches recorded at 280 mV. The open-
time distribution from a typical patch is fitted (least-squares) to a
single exponential decay with a time constant of 1.4 ms. Openings less
than 0.6 ms were excluded from the analysis to eliminate contributions
from the spontaneous openings of bLeu-99 3 Ser receptors, which
have a time constant of 0.3 ms (H. Zhang et al., personal communi-
cation).
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The present study illustrates the power of combining theo-
retical chemistry with modern molecular biology and electro-
physiology to produce high-precision insights into the workings
of a complex biological system. We conclude that aTrp-149 is
the primary cation–p binding site in the nAChR. When ACh
binds, the quaternary ammonium group makes van der Waals
contact with the 6-ring of the indole side chain. The aligned
position is highly conserved as a Trp in all muscle and neuronal
a subunits. In non-a subunits, however, the analogous residue
is not Trp, but is generally Tyr, Gln, and Leu in b, g, and d,
respectively. The residue is therefore not a ‘‘structural, canon-
ical residue,’’ as has been suggested for Trp-86, Tyr-151, and
Tyr-198 (1). The aligned position in 5-HT3 (serotonin) recep-
tors is also Trp, while it is Tyr in g-aminobutyric acid and
glycine receptors. It will be interesting to see whether these
aligned residues in other ligand-gated ion channels are also
cation–p binding sites. It will also be interesting to probe the
role of a149 in the complex pharmacology of both muscle and
neuronal nAChR. The only high-resolution structure of a
natural ACh binding site is that of acetylcholinesterase (32,
33). The quaternary ammonium group of ACh makes van der
Waals contact with Trp-84, as in the model proposed here.
Further away, but probably contributing to binding, is the
carboxylate of Glu 199. The primary carboxylate implicated in
the nAChR is dAsp-180ygAsp-174, on the basis of work by
Karlin (7) (Fig. 1). If the binding arrangement in the nAChR
is similar to that of the esterase, then aTrp-149 lies very close
to dAsp-180ygAsp-174 and therefore must be at the interface
between two subunits. This notion can be tested by using the
suppression methodology.
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